Amgen (NasdaqGS:AMGN) recently faced a legal setback, with a U.S. District Court jury finding the company liable for ...

Replimune Group shares fell 28% on heavy volume with no news, despite a promising July 2025 PDUFA date for RP1 in advanced ...

Amgen (NASDAQ:AMGN) will present at the 2025 RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Wednesday, May 21, 2025. Kave Niksefat, senior vice president of Global Marketing and ...

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Our editors picked the 50 companies that are smartest about how they combine innovative technology with an effective business model. Some are new companies and startups, while others have ...